CompletedNCT00563992
Lithium or valproate for bipolarity with suicidal behavior
About this title
Effectiveness of Lithium and Valproate in Treating High-Risk Bipolar Disorder
Read the official source — NCT00563992Medication studyAges 18–75United States
Understand this study
Who was this study for?
Listed age limits: 18 years to 75 years.
- Listed locations
- New YorkSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateJanuary 2001
- Recruitment status
- Completed
- Enrollment listed in the registry
- 98
- Sponsor
- New York State Psychiatric Institute
- Sponsor type
- Research institute
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 18 Years to 75 Years
- Official registry ID
- NCT00563992
- Official title
Show the full official title
Pharmacotherapy of High-Risk Bipolar Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
New York
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is New York State Psychiatric Institute, a research institute.
Did this study involve medication?
Yes. The study involved medication, including lithium and Valproic acid.
Who was this study for?
Listed age limits: 18 years to 75 years.
